EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure

Giuseppe Armentaro, Velia Cassano, Marcello Magurno, Carlo Alberto Pastura, Marcello Divino, Giandomenico Severini, Domenico Martire, Sofia Miceli, Raffaele Maio, Elisa Mazza, Tiziana Montalcini, Arturo Pujia und 1 weitere

Aging Clinical and Experimental Research · 2025

DOI: 10.1007/s40520-025-03049-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Clinical and Experimental Research, 2025. Verfasst von Giuseppe Armentaro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Geriatrics Division, "Renato Dulbecco" University Hospital of Catanzaro, 88100, Catanzaro, Italy. Hauptthemen laut MEDLINE: Heart Failure, Oxidative Stress, Sarcopenia, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli studi "Magna Graecia" di Catanzaro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sarcopenia is common in patients with heart failure (HF) and it is frequently associated with other comorbidities. Sarcopenia has been linked to an increased risk of major adverse cardiovascular events (MACE) in HF patients.

Aims

The aim of the present study was to evaluate, in a cohort of older adult’s patients affected by HF with reduced ejection fraction (HFrEF) and sarcopenia, already being treated with sacubitril/valsartan, the effect of add-on therapy with SGLT2i on clinical, functional abilities, muscle performance and effects on quality of life.

Methods

We enrolled 147 outpatients. A simple linear regression analysis was performed to assess the correlation between the change in Cardiac Index (CI) and Short physical performance battery (SPPB) values, expressed as (Δ) between baseline and follow-up (ΔT0-12), and several covariates.

Results

After 12 months of treatment, we observed an improvement in the inflammatory profile, moreover there was a reduction of the oxidative stress ( p < 0.0001) and platelets activation ( p < 0.0001) parameters. In addition, there was a significant increase in CI and global longitudinal strain and a statistically significant improvement in cognitive function, as shown by Mini-Mental State examination (MMSE) ( p < 0.0001) score and SPPB ( p < 0.0001). Considering ΔCI as dependent variation, Δ8-isoprotane resulted the major predictor, justifying 13.3% of its variation. When ΔSPPB was considered as dependent variable, Δ8-Isoprostane was the main predictor of ΔSPPB, justifying 54.6% of its variation. Discussion and conclusions This study demonstrated that the addition of SGLT2i to therapy leads to improvements in echocardiographic and sarcopenia-related parameters and biomarkers of oxidative stress and platelet activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureOxidative StressSarcopeniaSodium-Glucose Transporter 2 InhibitorsHumansAgedMaleFemaleEchocardiographyBiphenyl CompoundsValsartanAged, 80 and overDrug CombinationsAminobutyratesQuality of LifeAngiotensin Receptor AntagonistsChronic Disease

Stichwörter der Autor:innen

Cardiac indexHeart failureSGLT2iSarcopenia

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBiphenyl CompoundsValsartanDrug Combinationssacubitril and valsartan sodium hydrate drug combinationAminobutyratesAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Geriatrics Division, "Renato Dulbecco" University Hospital of Catanzaro, 88100, Catanzaro, Italy.
  • Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100, Catanzaro, Italy.
  • Geriatrics Division, Ospedale Civile San Giovanni di Dio, Azienda Sanitaria Provinciale di Crotone, 88900, Crotone, Italy.
  • Department of Clinical and Experimental Medicine, University Magna Grecia, 88100, Catanzaro, Italy.
  • Research Center for the Prevention and Treatment of Metabolic Diseases (CR METDIS), University "Magna Graecia" of Catanzaro, 88100, Catanzaro, Italy.
  • Geriatrics Division, "Renato Dulbecco" University Hospital of Catanzaro, 88100, Catanzaro, Italy. sciacqua@unicz.it.

Förderung

  • Università degli studi "Magna Graecia" di Catanzaro

Zitieren

APA

Armentaro, G., Cassano, V., Magurno, M., Pastura, C. A., Divino, M., Severini, G., Martire, D., Miceli, S., Maio, R., Mazza, E., Montalcini, T., Pujia, A., & Sciacqua, A. (2025). Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-025-03049-w

Vancouver

Armentaro G, Cassano V, Magurno M, Pastura CA, Divino M, Severini G, et al. Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure. Aging Clinical and Experimental Research. 2025. doi:10.1007/s40520-025-03049-w

BibTeX
@article{Armentaro2025,
  author = {Armentaro, Giuseppe and Cassano, Velia and Magurno, Marcello and Pastura, Carlo Alberto and Divino, Marcello and Severini, Giandomenico and Martire, Domenico and Miceli, Sofia and Maio, Raffaele and Mazza, Elisa and Montalcini, Tiziana and Pujia, Arturo and Sciacqua, Angela},
  title = {Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure},
  journal = {Aging Clinical and Experimental Research},
  year = {2025},
  doi = {10.1007/s40520-025-03049-w}
}
Kostenlos starten →